Gland Pharma seals Cenexi buyout pact: €120m option (2022)

Deal announcement and why it matters

Gland Pharma said it has signed an agreement to acquire 100% of Europe-based Cenexi Group, taking the next step in a transaction first structured through a put option in 2022. The company disclosed that its Singapore-based wholly owned subsidiary, Gland Pharma International PTE, entered into a share purchase agreement with FPCI Sino French Midcap Fund. The announcement formalises a full buyout pathway rather than a partial investment, and it signals a direct push into international manufacturing and development capabilities. For Gland Pharma, which operates as a contract development and manufacturing organisation (CDMO), the move is positioned as a foray into overseas markets.

Who is buying and who is selling

The buyer is Gland Pharma International PTE, Singapore, which is a wholly owned subsidiary of Gland Pharma. The seller is FPCI Sino French Midcap Fund. The asset being acquired is the full stake in Cenexi Group, described as Europe-based. The company said the share purchase agreement is being executed pursuant to the terms of the put option agreement signed earlier.

How the share purchase agreement links to the 2022 put option

Gland Pharma pointed to a put option agreement dated November 29, 2022, as the underlying framework for the acquisition. Under that agreement, Gland Pharma had outlined an acquisition of Cenexi Group for up to EUR 120 million, which it also described as around Rs 1,015 crore. The latest share purchase agreement indicates the put option structure has moved to an execution stage for full ownership. The company described the 2022 arrangement as a marker of its entry into international markets.

What a put option means in this context

The article explains that under a put option, an entity gets the right, not the obligation, to sell a specified amount or stake at a predetermined price. In practical terms, this structure provides a defined mechanism for the seller to exit at agreed terms, while the buyer aligns diligence and conditions for closing. Gland Pharma’s current announcement explicitly ties the share purchase agreement to that earlier put option agreement.

Deal value and other disclosed metrics

The 2022 put option agreement referenced an equity value not exceeding EUR 120 million, and other coverage in the provided text also mentions an enterprise value of EUR 230 million. The company’s communication described the EUR 120 million figure as roughly Rs 1,015 crore. No updated purchase consideration was specified in the provided text beyond referencing the earlier framework.

What Gland Pharma said it expects to gain

The provided text notes that the acquisition would give Gland Pharma access to know-how and development capabilities in sterile forms, including ophthalmic gel, needleless injectors, and hormones. This is consistent with a CDMO strategy centred on complex and regulated sterile products. The same coverage also describes the company’s strategic focus as expanding CDMO offerings in the European market and building a manufacturing presence in the region.

Funding and closing conditions mentioned

One portion of the provided material states that the transaction will be funded by internal resources with no recourse to third-party funding. The text also notes that the proposed acquisition remains subject to receipt of necessary regulatory approvals and satisfaction of certain conditions. These disclosures indicate the closing is not automatic and will depend on regulatory and procedural milestones.

Market reaction: stock moves cited in the coverage

The provided text includes multiple market snapshots and headlines indicating investor caution around the announcement period. One headline states the stock slipped 5% after the agreement to acquire Cenexi. Another excerpt states that at 11.56 am the scrip was trading about 4% lower at Rs 1,800 compared with the previous close of Rs 1,879.6. Separately, the text also notes a session where the stock traded 2.35% lower at Rs 1,833.75 against a previous close of Rs 1,877.95 on NSE.

Background: Cenexi and the timeline referenced

The provided text describes Cenexi as founded in 2004 and refers to Cenexi along with its subsidiaries. The repeated timeline references point to November 29, 2022 as the key date when the put option agreement was signed, followed by the current share purchase agreement with the fund to acquire the full stake. While the article does not provide an integration plan or post-acquisition structure, it frames the step as a deliberate international expansion.

Why the development matters for investors watching the CDMO space

Based on the disclosed details, the transaction is tied to building European CDMO presence and acquiring capabilities in sterile forms, which are typically specialised and compliance-intensive. Investors are likely to track how quickly regulatory approvals and conditions are met, because the company itself notes the transaction is subject to these steps. The market moves cited in the provided text show that the announcement did not automatically translate into a positive near-term stock reaction, even as the company outlined strategic benefits.

Conclusion

Gland Pharma, through its Singapore subsidiary, has signed a share purchase agreement with FPCI Sino French Midcap Fund to acquire 100% of Cenexi Group, moving forward under the put option framework dated November 29, 2022. The company has referenced a value of up to EUR 120 million (around Rs 1,015 crore) for the acquisition, with other coverage mentioning an enterprise value of EUR 230 million. Next, investors will watch for regulatory approvals and the satisfaction of closing conditions that the company has already flagged as prerequisites.